AssetMark Inc
NVLN

AssetMark Inc’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

AssetMark Inc’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-68
Closed – – 2208
2017
Q4 		$0 Buy
+68
New +$327 ﹤0.01% 2248
2017
Q1 		– Sell
-1
Closed – – 1514
2016
Q4 		$0 Buy
+1
New +$9 ﹤0.01% 1439

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

AssetMark Inc's NVLN Position: Q1 2018 in Review

AssetMark Inc sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q1 2018, closing a stake of 68 shares.

AssetMark Inc first reported a position in NVLN in Q4 2016 and held it in 2 quarters. The position peaked at $0 in Q4 2017. 68 funds tracked by Wall St. Rank hold NVLN as of Q1 2018.

  • AssetMark Inc reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q1 2018 after selling out during the quarter.
  • AssetMark Inc sold 68 Novelion Therapeutics Inc. Common Shares shares in Q1 2018.
  • AssetMark Inc first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 2 quarters.
  • AssetMark Inc's Novelion Therapeutics Inc. Common Shares position peaked at $0 in Q4 2017.
  • 68 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q1 2018.

Based on AssetMark Inc's 13F filing for Q1 2018, filed 16 May 2018.